Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells: a prospective, single blind, randomized controlled clinical trial

Next Previous
Trial Profile

Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells: a prospective, single blind, randomized controlled clinical trial

Status: Recruiting
Phase of Trial: Phase 0

Latest Information Update: 20 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mesenchymal stem cell therapy (Primary) ; Ruxolitinib (Primary) ; Antibacterials; Antivirals; Corticosteroid
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 20 Jun 2020 Status changed from active, no longer recruiting to recruiting.
  • 04 Jun 2020 New trial record
  • 28 May 2020 According to an Cincinnati Children's Hospital Medical Center media release, funding support for the JACI study came as part of an Emergency Research Project of Tongji Hospital, Huazhong University of Science and Technology (2020kfyXGYJ045), an Emergency Research Project of Hubei province (2020FCA006).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top